MedTrace Logo

Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation

NCT02910713 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2020-01-31

Study results available
· View outcomes & findings →

Summary

This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by the Controlled Adverse Environment model.

Conditions

  • Dry Eye Syndromes

Interventions

DEVICE

Intranasal Tear Neurostimulator

The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Michelle Senchyna · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2016-10-31
Completion
2016-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910713 on ClinicalTrials.gov